This FDA approval is based on results from the FLOW phase IIIb kidney outcomes trial investigating the effects of once-weekly Ozempic injection on major kidney and cardiovascular outcomes in adults with type 2 diabetes and CKD
Brush JE, Krumholz HM , Wright JS, Brindis RG, Cacchione JG, Drozda JP, Fasules JW, Flood KB, Garson A, Masoudi FA, McBride T, McKay CR, Messer JV, Mirro MJ, OToole M, Peterson ED, Schaeffer JW, Valentine CM
The placebo group lost 2.1% of body weight
Part IRespiratory Conditions
Unlike traditional fat-loss compounds, it is being studied as a non-stimulant option
Additionally, managing blood sugar becomes more complex, since the dual therapy can boost the risk of hypoglycemia, especially when used with insulin or sulfonylureas